Citigroup Inc Vincerx Pharma, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.0 - $0.0 $0 - $0	-429 Reduced 72.47%	163 $0
Q1 2022 May 12, 2022	SELL	$0.0 - $0.0 $0 - $0	-4,241 Reduced 87.75%	592 $2,000
Q4 2021 Feb 10, 2022	BUY	$0.0 - $0.0 $0 - $0	3,319 Added 219.22%	4,833 $49,000
Q3 2021 Nov 10, 2021	BUY	$0.0 - $0.0 $0 - $0	1,514 New	1,514 $24,000

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $6.57M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.